Evidence map›Paper›PMID 37110717›Full record

ArticleMolecules (Basel, Switzerland)2023

Synthesis and Evaluation of

Shreya Bendre, Zhengxing Zhang, Nadine Colpo, Jutta Zeisler, Antonio A W L Wong, François Bénard, Kuo-Shyan Lin

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.6field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Synthesis and Preclinical Evaluation of NovelPharmaceuticals (Basel, Switzerland) · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Shreya BendreDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Zhengxing ZhangDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Nadine ColpoDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Jutta ZeislerDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.
Antonio A W L WongDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0003-4617-9248
François BénardDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0001-7995-3581
Kuo-Shyan LinDepartment of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC V5Z 1L3, Canada.ORCID 0000-0002-0739-0780
Terry Fox Research Institute · CAUniversity of British Columbia · CA

Funding

CIHR PJT-180300
6 · The paper itself

Abstract

Fibroblast activation protein α (FAP-α) is a cell-surface protein overexpressed on cancer-associated fibroblasts that constitute a substantial component of tumor stroma and drive tumorigenesis. FAP is minimally expressed by most healthy tissues, including normal fibroblasts. This makes it a promising pan-cancer diagnostic and therapeutic target. In the present study, we synthesized two novel tracers, [

Indexed as

NeoplasmsPositron Emission Tomography Computed TomographyAnimalsFibroblastsGallium RadioisotopesHEK293 CellsHumansMiceThiazolidinesTissue DistributionGallium RadioisotopesThiazolidinescancer-associated fibroblasts (CAFs)FAP inhibitors (FAPIs)fibroblast activation protein α (FAP-α)Gallium-68PET imagingtargeted radiopharmaceuticals

Identifiers

PMID37110717
PMCPMC10145249
OpenAlexW4367320619

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.